共 69 条
[1]
Klein R(1999)Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III Ophthalmology 106 1056-1065
[2]
Klein BE(2006)Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 1432-1444
[3]
Jensen SC(2009)Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 57-65
[4]
Brown DM(2006)Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363-372
[5]
Kaiser PK(2006)Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 1419-1431
[6]
Michels M(2009)VEGF trap-eye for the treatment of neovascular age-related macular degeneration Expert Opin Investig Drugs 18 1573-1580
[7]
Brown DM(2009)A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration Ophthalmology 116 214-218
[8]
Michels M(2011)Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 1897-1908
[9]
Kaiser PK(2016)Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trails Ophthalmology 123 1751-1761
[10]
Avery RL(2012)Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 1399-1411